Radiopharm Theranostics LtdRADX
Price (close)
$1.57
Market cap
$22.9M
P/E
—
Revenue (FY)
$3.6M
Net income
-$38.3M
Dividend yield
—
1-year total return
-72.7%
Net margin
-1055.3%
Revenue growth
1114.3%
Debt / equity
—
What Radiopharm Theranostics Ltd does.
company that aims to develop and commercialize platforms of radiopharmaceutical products for both therapeutic and diagnostic applications
validated radiopharmaceutical technologies that are in both pre-clinical and clinical stages of development. These technologies span all
size molecules comprising peptides, small molecules and antibodies attached to medical quality radioisotopes. We are pursuing registration
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | $292,359 | $299,228 | $3.6M |
| Net income | — | -$34.6M | -$47.9M | -$38.3M |
| Free cash flow | — | -$23.2M | — | — |
More on RADX.
- Radiopharm Theranostics Ltd summary
- Radiopharm Theranostics Ltd financial statements
- Radiopharm Theranostics Ltd key metrics
- Radiopharm Theranostics Ltd health scores and style box
- Radiopharm Theranostics Ltd earnings
- Radiopharm Theranostics Ltd dividends
- Radiopharm Theranostics Ltd valuation
- Radiopharm Theranostics Ltd ownership and insiders
- Radiopharm Theranostics Ltd peers
Figures from Radiopharm Theranostics Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.